Technologies

A biosensor based on magnetic microspheres functionalized with a DNA-aptamer was developed for the specific biomonitoring of biological contaminants (mycotoxins) in urine.

AIDD is an integrated tool and a radically new way to discovery new drugs for neurodegenerative diseases (Alzheimer’s, Epilepsy, Ageing, etc.).

The development of genome editing tools has revolutionized the way we think and deal with genetics. The use of Cas9 or its variants allows modifications of specific sites in the human genome by inducing deletions and insertions in a more or less controlled way. In recent years, a new class of tools for genome editing has emerged: the base editors (BE), which result from the fusion of a modified Cas9, which serves to direct the BE to the target, and an active deaminase acting on the DNA, which mediates the C> T or A> G editing.

Aptamers, short structured single-stranded oligonucleotides binding at high affinity to a given target protein, are selected from large combinatorial libraries through repeated cycles of incubation of the library with the target, recovery and amplification of target-bound oligonucleotides (SELEX technology, Systematic Evolution of Ligands by EXponential enrichment). SELEX can be applied to select aptamers against a known target protein or against a specific cell phenotype, without any prior knowledge of the specific target, leading to new biomarkers discovery.

Time-correlated single photon counting (TCSPC) is regarded as the “gold-standard” method for fluorescence lifetime measurements. However, TCSPC requires using highly sensitive detectors, not suitable for measurements under bright light conditions, thereby making the use impractical in clinical settings. The invention described here solves this problem by synchronizing the fluorescence detection with an external light source.

The Biocrystal Facility, a large multidisciplinary laboratory established at the Institute of Molecular Biology and Pathology (IBPM) of CNR, in collaboration with the Biochemistry Department of Sapienza University aims at supporting the italian scientists and the pharmaceutical companies in the research to find new drug and vaccine against the endemic and epidemic diseases through structure-based drug design.

The dramatic global health emergency due to the SARS-CoV-2 pandemic requires new diagnostic devices capable of identifying the presence of virus particles in patient biological samples. In this direction, the development of an innovative low-cost test, which provides the result within a few minutes, which is reproducible and which can reveal the direct presence of even a few viral particles, would be of fundamental importance for the monitoring and containment of the pandemic.

The virtual dynamic docking, carried out in the MOLBD3 lab of the Institute of Biophysics, allows the identification of new drugs through the structural information deriving from the study of target proteins, responsible for some human pathologies. In particular, we screen drugs or small molecules (commercial/own libraries) against known protein sites, surface cavities, surfaces of protein-protein interactions (fixed/rigid hotspots) or structural transition states (dynamic hotspots).

In the last years, genetics played a strategic role in the identification of therapeutic targets for complex diseases. Genetic studies identified thousands of variants contributing to disease onset and/or to the influence of measurable features (phenotypes) impacting health. The mechanism of action by which they modulate diseases and phenotypes is still unknown for the vast majority.

Detection devices for the presence of molecules of interest (analytes) enjoyed a renewed burst with the introduction of biological components (biosensors). Their high specificity is often used in various fields, from environmental monitoring and biomedicine to the protection and promotion of agri-food products. However, the high cost of production and the lack of compatibility with mass sampling (high-throughput) sometimes limit their use.

In our recent publication we identified a group of  bladder cancer-specific ncRNA, called T-UCRs that are the most up-regulated in bladder cancer patient samples compared with normal bladder urothelium.

The NanoMicroFab infrastructure, support companies operating in the field of micro and nanoelectronics through the supply of materials, development of processes, design, fabrication and characterization of materials and devices. NanoMicroFab makes use of existing CNR facilities of the Institute of Microelectronics and Microsystems, the Institute of Photonics and Nanotechnologies and the Institute for the Structure of Matter and provides: • a complete line of development of devices based on wide band gap semiconductors.

The technology concerns planar optical antennas composed of thin metal films and dielectric materials for the efficient direction of the light emitted by light sources, such as fluorescent molecules and bio-markers. They consist of a reflector layer, adjacent to the substrate, and a director, semi-reflective, between which the emitter is positioned, integrated into a homogeneous dielectric layer.

This is a high-throughput sequencing based method to map euchromatin and heterochromatin accessibility. The method is based on the sequential extraction of distinct nuclear fractions containing: soluble proteins (S1 fraction); the surnatant obtained after DNase treatment (S2 fraction); DNase-resistant chromatin extracted with high salt buffer (S3 fraction); and the most condensed and insoluble portion of chromatin, extracted with urea buffer that solubilizes the remaining proteins and membranes (S4 fraction).

TNBC affects around 170,000 patients worldwide each year and accounts for 15-20% of breast cancer; compared to other types of breast cancer, TNBC is more aggressive and precocious. Its diagnosis, made difficult by the existence of subtypes with different characteristics, is fundamental to establish prognosis and personalized therapy. Nucleic acid aptamers are highly selective low-molecular-weight molecules, synthesizable at low cost and easily modifiable, capable of binding and detecting tissue markers ("aptahistochemistry”). Our team has iden